Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

Merck’s commitment to HIV For more than 35 years, Merck has been committed to scientific research and discovery in HIV leading to scientific breakthroughs that have helped change HIV treatment.